上海醫藥(601607.SH):擬出資5億元參設前沿創新中心 其將開展從新靶點發現到Ⅱ期臨牀研究的創新研發工作
格隆匯9月6日丨上海醫藥(601607.SH)公佈,公司擬作為股東單位之一,出資5億元人民幣與上海海外有限公司、上海二醫投資管理有限公司、上海張江(集團)有限公司共同設立上海生物醫藥前沿產業創新中心有限公司(簡稱“前沿創新中心”或“合資公司”)。此次交易構成關聯交易。
上海生物醫藥前沿產業創新中心有限公司定位於開展從新靶點發現到Ⅱ期臨牀研究的創新研發工作,集聚上海市“名校”、“名企”、“名院”尖端科研力量,採取市場化運作方式,通過多種形式引進高端人才,緊扣新藥從先導化合物發現到候選藥物分子的獲得、再到臨牀研究(Ⅱ期臨牀以前)的研發流程,自建系統化、高效率、高級別、可及性強的藥物通用型發現技術平台及孵化轉化平台,成為高校院所和中小醫藥企業原創成果孵化轉化的堅實橋樑。
此次交易完成後,前沿創新中心將被納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.